Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Encapsidation of Heterologous Entities into Virus-like Particles


Stanford Reference:

08-365


Abstract


Stanford investigators have developed a method to package exogenous entities, inside virus-like particles (VLPs) during cell-free protein synthesis. A variety of cargo, such as sRNAi, toxic material, small proteins, probes, or markers, can be encapsulated by the particle. This technology has a variety of applications, including vaccination, drug delivery, gene delivery, cancer treatment, and diagnostic imaging.

Applications


  • Drug delivery - by encapsidating pharmaceutically active molecules
  • Increase vaccine efficacy - by including encapsidated immune stimulating entities with vaccines
  • Diagnostic imaging - by encapsidating imaging enhancing agents
  • Gene delivery - by encapsidating nucleic acids

Advantages


  • Direct access - any portion of the transcription/translation/VLP assembly environment can be optimized in the cell free environment
  • Fewer steps - cargo is encapsidated at the time of VLP synthesis
  • Cargo control - direct control over the concentration cargo molecules added to the process
  • Less contamination - the environment is more dilute than that of a cell and no endogenous RNA, which might contribute to impurities, is transcribed

Publications



Stage of Research


The investigators have demonstrated use of this method to encapsidate a fluorophore. Additionally, they have successfully used cell-free synthesis to encapsidate a firefly luciferase shRNA into VLPs.

Innovators & Portfolio



Patent Status



Date Released

 3/2/2016
 

Licensing Contact


Irit Gal, Senior Licensing Associate
650-723-1586 (Business)
Login to Request Information

[-] Map/Timeline

92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)

more technologies »

Related Keywords


therapeutic: vaccine   cancer vaccine   gene delivery   therapeutic: anticancer   therapeutic: antiviral   therapeutic: drug delivery   therapeutic: imaging   therapeutic: immunotherapy   therapeutic: pathogen   therapeutic: peptides   therapeutic: proteins   therapeutic: RNAi   therapeutic: small molecule   therapeutic: viral   Virus-like particles (VLPs)   research tool: protein synthesis   cell-free protein synthesis   
 

   

  

Also of Interest...
92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)

Recently Viewed...
S08-365 Encapsidation of Heterologous Entities into Virus-like Particles